Merck & Co. said Friday it would discontinue developing the osteoporosis drug odanacatib and not seek regulatory approval for the treatment because it carries a higher risk of stroke.
New Jersey-based Merck said it decided to stop development after an independent analysis confirmed an increased risk of stroke with use of the drug. The data from the analysis will be presented this month at the American Society for Bone Mineral Research.
Filed Under: Drug Discovery
